Novo Nordisk stock steadies as lower-dose Wegovy pill trial advances
Published on 08/22/2026 at 08:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk (ISIN DK0060534915) stock is trading in a tight range in late August 2026, with the company balancing a new Phase 3 obesity trial against a modest share-price pullback over the past month as investors reassess the growth trajectory of its GLP-1 franchise.
As of August 21, 2026, one US-listed Novo Nordisk share traded at $47.02 during the latest session, with an intraday range between $46.35 and $47.11 and a daily gain of 1.42 percent, indicating calm trading despite sector headlines. On the company’s primary Nasdaq Copenhagen line, the latest close of DKK300.85 on August 21, 2026 reflected a 1.59 percent daily increase and a 2.09 percent gain since the start of 2026, even as the stock remained 7.50 percent below its level at the beginning of the year.
Lower-dose Wegovy pill trial moves into Phase 3
Per a recent clinical-trial update, Novo Nordisk has begun enrolling patients in a Phase 3 study that tests lower maintenance doses of its oral Wegovy pill, formally oral semaglutide, in adults with obesity or overweight in the United States and Europe. The OASIS 5 trial, which started on August 12, 2026, is designed as a placebo-controlled study at 62 sites and evaluates two undisclosed lower doses of oral semaglutide together with a reduced-calorie diet and increased physical activity.
The primary endpoint in OASIS 5 is the percentage change in body weight after 60 weeks of treatment, while secondary measures include the share of participants who lose at least 5, 10, or 15 percent of their starting weight by the end of the trial. Previous mid-stage data for the oral Wegovy pill in March 2026 showed an average weight loss of 10.7 percent after 42 weeks at currently approved dose levels, with an adverse-event profile that was similar to placebo, a result that disappointed some investors when compared with the up to 25 percent weight-loss levels achieved by injectable GLP-1 drugs.
The new study specifically targets lower maintenance doses to determine whether patients can sustain meaningful weight loss with less drug exposure, which could help reduce gastrointestinal side effects and potentially improve long-term adherence. For investors, the key quantitative comparison will be how weight-loss percentages at these lower doses stack up against both the earlier 10.7 percent midpoint result at higher oral doses and the more than 20 percent weight-loss rates seen with next-generation injectables in prior Phase 3 programs.
Obesity race with Eli Lilly shapes investor sentiment
The broader GLP-1 weight-loss race remains central to Novo Nordisk’s equity story, and recent sector analysis highlights diverging revenue trajectories for the company and its main US rival. In the second quarter of 2026, Novo Nordisk generated revenue of 17 trillion South Korean won, which represented a 7 percent increase year over year, underlining continued growth but at a slower pace than some investors had hoped. Over the same period, its US competitor reported revenue of 32 trillion won, a 48 percent year-over-year jump that widened the growth gap between the two leaders in obesity pharmacotherapy.
Within Novo Nordisk’s second-quarter 2026 results, combined sales of its obesity and diabetes GLP-1 brands Wegovy and Ozempic totaled 11 trillion won, highlighting the franchise’s importance to the top line and confirming that a majority of company revenue now comes from weight-management and diabetes-care therapies. During that same quarter, rival GLP-1 products zepbound and Mounjaro delivered 21 trillion won in sales for the competing firm, almost double Novo Nordisk’s GLP-1 revenue base and a concrete indication that the rival’s GLP-1 portfolio is currently scaling faster in absolute terms.
On the stock-performance side, recent market commentary notes that Novo Nordisk shares on the New York Stock Exchange declined 7 percent between July 21, 2026 and August 20, 2026, while its main competitor’s stock advanced 6 percent over that period, a 13 percentage-point performance gap driven largely by differing expectations for future GLP-1 growth. Analysts cited this combination of slower revenue expansion and more cautious earnings guidance as a factor that tempered enthusiasm for Novo Nordisk in the near term, even though the company continues to grow and to invest in a broad obesity pipeline that includes oral agents and combination therapies.
CagriSema and amylin-based combinations add pipeline depth
Beyond oral semaglutide, Novo Nordisk is advancing a series of combination therapies that seek to exploit amylin biology alongside GLP-1 mechanisms in order to enhance weight loss while managing side effects. One of the most advanced candidates, CagriSema, pairs the amylin analogue cagrilintide with semaglutide and is described as the first once-weekly combination of GLP-1 and amylin analogues to reach regulatory filing for weight management in major markets. In the REDEFINE 1 Phase 3 study, conducted in adults with obesity, CagriSema produced an average weight reduction of roughly 23 percent over 68 weeks, outperforming the individual components when used alone and showing the potential for combination approaches to push weight-loss efficacy toward the mid-twenties in percentage terms.
Novo Nordisk submitted a New Drug Application for CagriSema to the US Food and Drug Administration in December 2025, and investors expect a regulatory decision during 2026, making this one of the company’s key pipeline catalysts in the medium term. In parallel, the company is also testing amicretin, which combines an amylin analogue with semaglutide, in both oral and injectable formulations. Clinical results published in 2025 indicated that the highest injectable amicretin dose delivered an average weight loss of 24.3 percent, placing it firmly in the range of leading next-generation injectable therapies and underscoring the strategic importance of amylin-based combinations for Novo Nordisk’s long-term growth.
For equity investors, these pipeline numbers reinforce the notion that Novo Nordisk is positioning itself not only as a GLP-1 leader but also as a major player in the emerging class of multi-hormone combinations. The comparison between the 10.7 percent weight loss seen in mid-stage oral Wegovy data and the 22 to 24 percent reductions achieved with CagriSema and amicretin highlights both the upside for injectables and the challenge of narrowing the efficacy gap for oral regimens, a key commercial priority given patient preferences for pills over injections.
Valuation and recent share-price context
In terms of valuation metrics, publicly available data show Novo Nordisk trading at a premium price-to-earnings multiple versus many traditional pharmaceutical peers, reflecting the market’s expectation that GLP-1 and obesity-related revenue will continue to expand over the coming years. While exact real-time valuation ratios fluctuate alongside earnings updates and price movements, historical series indicate that the company has often commanded a high-teens to mid-twenties trailing P/E ratio through 2025 and into 2026, in line with other high-growth healthcare names. Investors are now scrutinizing whether second-quarter 2026 growth of 7 percent and a 7 percent share decline over the past month are early signals of multiple compression or simply a temporary pause after a multi-year rally.
From a technical perspective, some European commentary notes that Novo Nordisk’s Copenhagen-listed shares recently traded close to their 200-day moving average. One report highlighted a late-week close at the equivalent of 39.98 euros and a 200-day moving average of 40.23 euros, implying that the stock was only 0.6 percent below this long-term trend line. That tight spread suggests that, despite the recent pullback, the stock has not broken decisively below its medium-term technical support, a factor that many chart-focused investors monitor when evaluating entry and exit points in high-profile growth names.
The combination of a 7 percent revenue increase in the second quarter of 2026, an 11 trillion won contribution from Wegovy and Ozempic, and a 7 percent share-price decline over the past month presents a nuanced picture for current shareholders. On one hand, growth remains positive and the obesity pipeline is deep; on the other, the relative underperformance versus a rival whose revenue grew 48 percent year over year underscores that Novo Nordisk may need additional catalysts, such as successful OASIS 5 results or a timely CagriSema approval, to reaccelerate investor enthusiasm.
Wegovy pill as flagship obesity product
A central commercial pillar for Novo Nordisk is the Wegovy family, which now includes both injectable and oral semaglutide formulations aimed at chronic weight management. The oral Wegovy pill, introduced as a GLP-1 therapy for obesity, is approved in a starter dose of 1.5 milligrams, with a titration schedule that steps patients up through 4 milligrams and 9 milligrams to a current maximum maintenance dose of 25 milligrams. This dosing structure is designed to help patients acclimate to GLP-1 therapy while balancing efficacy and tolerability.
The decision to launch the OASIS 5 trial for lower maintenance doses reflects an effort to fine-tune this regimen and to identify the lowest dose that still maintains weight loss over the long term. Because previous mid-stage results showed 10.7 percent average weight loss over 42 weeks at approved dose levels, any Phase 3 evidence that smaller maintenance doses can preserve weight-loss benefits would be an important differentiator, particularly for patients who experience gastrointestinal side effects or who are sensitive to higher GLP-1 exposure. The trial’s design, which includes endpoints such as the proportion of patients achieving at least 10 or 15 percent weight loss, will give clinicians and payers concrete data for comparing outcomes across different dosing strategies.
In addition to efficacy, long-term safety and patient adherence are critical for a chronic therapy like Wegovy. By testing lower doses against a reduced-calorie diet and increased physical activity, the OASIS 5 program aims to generate real-world-relevant evidence that can inform both clinical guidelines and reimbursement decisions. For Novo Nordisk stock, the outcome of this trial will feed directly into the narrative about how broad and sustainable the company’s obesity franchise can be, and whether it can defend or expand its market share against rapidly advancing competitors.
Current stock level and investor takeaway
On US markets, Novo Nordisk’s American depositary shares most recently changed hands at $47.02 with a session high of $47.11 and a low of $46.35 as of August 21, 2026, reflecting a modest 1.42 percent gain on the day in USD terms. In Copenhagen, the primary listing closed at DKK300.85 on the same date, with a 1.59 percent daily increase and a 2.09 percent gain since the start of 2026, even as the stock remained 7.50 percent below its early-year level.
For investors, the key quantified elements are the 7 percent year-over-year revenue growth in the second quarter of 2026, the 11 trillion won in GLP-1 revenue from Wegovy and Ozempic, and the 7 percent share-price decline over the past month compared with a 6 percent rise in the main competitor’s stock. These figures highlight both the strength and the current challenges of Novo Nordisk’s position: a powerful but contested GLP-1 franchise, a promising pipeline featuring products like CagriSema and amicretin, and a valuation that now has to balance strong historical performance against signs of slower relative growth.
Read more
Latest Novo Nordisk US share price overview
GLP-1 obesity therapies
Novo Nordisk’s core business centers on GLP-1-based therapies for diabetes and obesity, with Wegovy and Ozempic representing its flagship brands in these categories. These drugs work by mimicking the gut hormone GLP-1, which helps regulate blood sugar and appetite, leading to reduced caloric intake and improved glycemic control. In the second quarter of 2026, the company’s GLP-1 portfolio contributed 11 trillion won in combined sales from Wegovy and Ozempic, underscoring the extent to which this therapeutic class drives overall revenue.
The company’s newer oral semaglutide formulation extends this GLP-1 mechanism into a pill format, offering patients who are reluctant to use injections a different path to weight management. The OASIS 5 trial of lower maintenance doses for the oral Wegovy pill fits within a broader strategy of diversifying delivery options and tailoring treatment intensity to different patient segments. Combined with pipeline agents like CagriSema and amicretin, these efforts indicate that Novo Nordisk is trying to build a layered obesity-treatment portfolio, spanning injectables, oral medications, and multi-hormone combinations that can address varying levels of obesity severity and comorbidities.
Stock snapshot and listing details
Novo Nordisk stock trades primarily on the Nasdaq Copenhagen exchange under the ticker NOVO B, with a recent closing price of DKK300.85 as of August 21, 2026 and a year-to-date gain of 2.09 percent offset by a 7.50 percent decline from the start of the year’s higher levels. The company’s American depositary shares, listed on the New York Stock Exchange under the ticker NVO, most recently closed at $47.02, with an intraday range between $46.35 and $47.11 and a 1.42 percent gain during the latest session. These cross-listing figures indicate that Novo Nordisk shares currently sit modestly above their 200-day moving average on European markets and that recent price action has been relatively contained despite broader volatility in obesity-focused exchange-traded funds.
While short-term performance has lagged that of its primary US rival, the combination of a 7 percent revenue increase in the second quarter of 2026, an 11 trillion won GLP-1 revenue contribution, and a robust obesity pipeline gives investors concrete metrics with which to evaluate the stock. Future catalysts, including the outcome of the OASIS 5 trial and regulatory decisions on CagriSema, will likely play a significant role in determining whether Novo Nordisk stock can regain momentum and close the recent performance gap within the GLP-1 and obesity-treatment sector.
Fact box
Company: Novo Nordisk A/S
ISIN: DK0060534915
Ticker: NOVO B (Nasdaq Copenhagen), NVO (NYSE)
Exchange: Nasdaq Copenhagen, New York Stock Exchange (ADR)
Price (as of August 21, 2026, latest close): $47.02 USD (ADR), DKK300.85 (Nasdaq Copenhagen)
Sector / Industry: Healthcare / Pharmaceuticals and Biotechnology
Index membership: C25 (Copenhagen), various global healthcare indices
